| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Periplocoside N targets insects, exhibiting insecticidal activity against red fire ants (Solenopsis invicta). As a pregnane glycoside, it may interact with insect-specific molecular targets. The compound has also been studied for cytotoxic, anti-inflammatory, and immunomodulatory effects, suggesting activity on mammalian cells and immune pathways. Its mechanism may involve disruption of cellular membranes or interference with steroid hormone signaling pathways. However, specific molecular targets have not been fully characterized.
|
|---|---|
| ln Vitro |
In vitro, Periplocoside N exhibits insecticidal activity against red fire ants. The compound has been studied for cytotoxic, anti-inflammatory, and immunomodulatory effects. As a pregnane glycoside from Periploca sepium, it may have diverse biological activities. However, detailed in vitro activity data including IC₅₀ values are not extensively published. Further studies are needed to characterize its potency and mechanisms of action in various biological systems.
|
| ln Vivo |
In vivo, Periplocoside N has been studied for its insecticidal activity. The compound is a natural product from Periploca sepium, a plant used in traditional herbal medicine. Its potential cytotoxic, anti-inflammatory, and immunomodulatory effects suggest possible therapeutic applications. However, detailed in vivo efficacy data from mammalian models are not extensively published. Further research is needed to evaluate its therapeutic potential.
|
| Enzyme Assay |
In vitro assays for Periplocoside N typically involve evaluation of insecticidal activity against red fire ants. The compound's structure can be confirmed by NMR and MS. Purity is typically assessed by HPLC. Cytotoxic activity can be evaluated using cancer cell lines with MTT or SRB assays. Anti-inflammatory activity can be assessed by measuring cytokine production in immune cells.
|
| Cell Assay |
In vitro cellular assays for Periplocoside N could include evaluation of cytotoxicity in cancer cell lines, anti-inflammatory activity in immune cells, and immunomodulatory effects in lymphocyte cultures. Cells are treated with the compound and cell viability, cytokine production, or immune cell proliferation is measured. The compound is typically handled as a powder and may be soluble in appropriate organic solvents for cell culture applications.
|
| Animal Protocol |
In vivo animal experiments for Periplocoside N have been conducted for insecticidal activity studies. For mammalian studies, potential applications in cancer and autoimmune disease research would involve rodent models. However, detailed experimental protocols for mammalian in vivo studies are not extensively published in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Periplocoside N are characteristic of pregnane glycosides. The compound has a molecular weight of 464.31 g/mol and molecular formula C₂₇H₄₄O₆. As a glycosylated steroid, it is expected to have moderate lipophilicity and may have limited oral bioavailability due to the sugar moiety. The compound may undergo deglycosylation in the gastrointestinal tract. Storage: powder at -20°C for 3 years or 4°C for 2 years.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Periplocoside N is not extensively documented. As a plant-derived glycoside from Periploca sepium, its toxicity may depend on the dose and route of administration. Some pregnane glycosides can have significant biological activity. Comprehensive toxicological evaluations have not been reported. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
According to reports, Periploca sepium contains PeriplocosideN, and relevant data is available for reference.
Periplocoside N (CAS# 39946-41-3, molecular formula C₂₇H₄₄O₆, molecular weight 464.31) is a pregnane glycoside from Periploca sepium. It has insecticidal activity against red fire ants and has been studied for cytotoxic, anti-inflammatory, and immunomodulatory effects. Also known as 北五加皮苷N. No clinical trials or regulatory approvals have been identified. |
| Molecular Formula |
C27H44O6
|
|---|---|
| Molecular Weight |
464.63
|
| Exact Mass |
464.314
|
| CAS # |
39946-41-3
|
| PubChem CID |
15608626
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.303
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
33
|
| Complexity |
785
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H](C)[C@]2(CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)O)C)C)O)O)O
|
| InChi Key |
MQSVACYEBUOKAY-NOQMFQFLSA-N
|
| InChi Code |
InChI=1S/C27H44O6/c1-15-24(30)22(29)14-23(32-15)33-16(2)27(31)12-9-21-19-6-5-17-13-18(28)7-10-25(17,3)20(19)8-11-26(21,27)4/h5,15-16,18-24,28-31H,6-14H2,1-4H3/t15-,16+,18+,19-,20+,21+,22-,23+,24-,25+,26+,27+/m1/s1
|
| Chemical Name |
(2R,3S,4R,6S)-6-[(1S)-1-[(3S,8R,9S,10R,13S,14S,17R)-3,17-dihydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethoxy]-2-methyloxane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1523 mL | 10.7613 mL | 21.5225 mL | |
| 5 mM | 0.4305 mL | 2.1523 mL | 4.3045 mL | |
| 10 mM | 0.2152 mL | 1.0761 mL | 2.1523 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
